A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)

Inclusion Criteria: * Male and female subjects minimum 18 and maximum 70 years of age * Body Mass Index (BMI) = 36 kg/m2 * Subjects with COPD: Diagnosis of COPD (emphysema and/or chronic bronchitis), * smoking history =10 years, chronic cough present intermittently or daily with or without sputum and/or dyspnea upon exertion. * Subjects with COPD: Pulmonary Function Tests - FEV1 =50% (NHANES) III * Predicted; FEV1/FVC \< 70 % (NHANES) III; TLC =80% of Predicted (ITS) and DLco(unc) =50% of Predicted (Miller) * Subjects without COPD: PFTs: FEV1 = 70% NHANES III Predicted; TLC =80% of * Predicted (ITS) and DLco(unc) =80% of Predicted (Miller) Exclusion Criteria: * History of pre-diabetes or diabetes * Previous or current treatment with any anti-diabetic drugs * Serum creatinine \> 2.0 mg/dL in males and \> 1.8 mg/dL in females * Active smokers defined as having smoked their last cigarette, pipe, and/or cigar without the previous 6 months * Previous exposure to any inhaled insulin product or investigational medicines/devices within the previous 30 days prior to entry or participation * Clinically significant major organ disease * Female subjects of childbearing potential not practicing adequate birth control * Subjects with COPD: Significant improvement in pre-to post-bronchodilator spirometry (defined as an increase of 12% AND 200 mL in either FVC or FEV1); * Any clinically important pulmonary disease except mild or moderate COPD * Subjects without COPD: Any important pulmonary disease confirmed by pulmonary function testing and/or radiologic findings